Venn Life Sciences Share News (VENN)
VENN Share
VENN Share
VENN Share
VENN Share
VENN
VENN Share
VENN Broker
VENN Directors
VENN Financial
VENN
VENN Short
VENN
(ShareCast News) - Drug trial company Venn Life Sciences has completed the sale of its stake in Innovenn UK innovation unit to Integumen for up to £4.74m that will see it retain a majority stake as the newly created skin science company looks to float on AIM. Integumen has been set up by Venn's dire
Read more(ShareCast News) - Venn Life Sciences has signed a new contract worth €2.5m with Sedana Medical for a phase III trial. The trial, which is confined to patients in Germany and commences immediately, will confirm the efficacy and safety of sedation with isoflurane in ventilated intensive care patients
Read more(ShareCast News) - Venn Life Sciences chairman Allan Wood bought £50,000 worth of the contract clinical research provider's shares, it was revealed on Wednesday. Wood picked up 230,000 shares in two purchases at an average price of 21.67p. Shares in the AIM-listed company have drifted since interim
Read more(ShareCast News) - Drug development and clinical trial management contract research organisation Venn Life Sciences confirmed on Thursday that its shareholders had approved of a deal to offload Innovenn UK. The AIM-traded company had announced on 4 October that its wholly owned subsidiary, Venn Life
Read more(ShareCast News) - Contract research organisation Venn Life Sciences announced on Tuesday that its wholly owned subsidiary, Venn Life Sciences Limited, has entered into a conditional agreement under which it and Lynchwood Nominees Limited, as custodian for the Helium Rising Stars Fund, would sell th
Read more(ShareCast News) - Drug development services and clinical trial management provider Venn Life Sciences announced its unaudited interim results for the six months to 30 June on Wednesday, with revenue of €9.06m, up from €4.25m in the first half of last year. The AIM-traded firm had EBITDA profit of €
Read more(ShareCast News) - Contract research organisation Venn Life Sciences said it has signed a new contract worth €2.8m with an unnamed European biotechnology client. Venn, which provides drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical dev
Read more
(ShareCast News) - Venn Life Sciences was working to please investors on Friday, revealing its expectations for the year ahead of its full-year results. The AIM-listed drug development services company said revenues for the full year to 31 December were expected to be at least double the previous ye
Read more